News Focus
News Focus
icon url

Investor2014

02/12/25 7:43 AM

#482885 RE: hnbadger1 #482883

Yes that is always the hope and so far never paid off.
icon url

hnbadger1

02/12/25 8:02 AM

#482886 RE: hnbadger1 #482883

“Potential “ three times in one quote…humm
I’m sure the shorts will jump on that.
Yes, I have become critical of the companies choice of wording in the PR quotes!

"We are receiving growing support from stakeholders for the potential to advance a novel treatment for early Alzheimer's disease with convenient oral dosing with potential clinical meaningful benefit," said
Christopher U Missling, PhD,
President and Chief Executive Officer of Anavex. "We are excited to potentially making a difference for individuals suffering from Alzheimer's disease, by presenting a scalable treatment alternative alongside the ease of oral administration."
Bullish
Bullish
icon url

rx7171

02/12/25 9:02 AM

#482893 RE: hnbadger1 #482883

Two pieces I found new.

First read out of 3-71 phase 2b in schizophrenia first half this year.

MABs require MRI every three weeks. Enormous cost per year.
icon url

rx7171

02/12/25 9:02 AM

#482894 RE: hnbadger1 #482883

Two pieces I found new.

First read out of 3-71 phase 2b in schizophrenia first half this year.

MABs require MRI every three weeks. Enormous cost per year.